You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A novel monobody-drug conjugate to treat mutant Ras multiple myeloma

    SBC: TEZCAT Laboratories LLC            Topic: 102

    Project Summary: Multiple myeloma is an incurable hematologic malignancy with an expected median survival of 7-8 years. The proteasome inhibitors, bortezomib, carfilzomib and the recently approved ixazomib, are a mainstay of current myeloma treatment. Despite an initial response rate approaching 90% to proteasome inhibitor-containing combinations, all patients relapse and eventually become resista ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Genomics MediaBook for a Technology Society

    SBC: CENTER LINE PRODUCTIONS            Topic: N/A

    DESCRIPTION (provided by applicant): The Genomics Revolution and the resultant explosion of knowledge in genomics are shaping our futures. Therefore, it is crucial that knowledge of genomics is broadly disseminated, so that future scientists, educators, policy makers, community leaders, and heads of households can harness the beneficial power of genomic science. Given the indiscriminate impact of ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  3. Modulation of the gut microbiome to enhance efficacy of immunotherapy in pancreatic adenocarcinoma

    SBC: PERIOMICS CARE LLC            Topic: 102

    Abstract Pancreatic ductal adenocarcinoma (PDA) is among the ten most common cancers for both men and women. According to CDC the incidence rates of pancreatic cancer have been rising by almost 1.2% each year over the last 10 years. The 5-year survival rate is less than 7%. Despite the recent success of checkpoint blockade- based monotherapy in human melanoma and non-small cell lung cancer, many P ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. An IGF-1R-targeting peptide drug conjugate for targeted treatment of atypical teratoid/rhabdoid tumors

    SBC: NIGHTHAWK BIOSCIENCES, INC.            Topic: 102

    PROJECT SUMMARY Atypical teratoid/rhabdoid tumors (AT/RT) are rare embryonal central nervous system malignancies that occur in early childhood and are lethal. Current treatment strategies for children diagnosed with AT/RT are limited to surgery, radiation, and chemotherapy, but to date, none of these have successfully improved survival beyond 18 months, and most are associated with significant tox ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Validating novel DNA repair deficient cancer therapy targets and small molecule compounds

    SBC: ANANEO THERAPEUTICS INC            Topic: 102

    Abstract Single-strand DNA repair (ssDR) is critical for preventing genomic catastrophe. AnaNeo Therapeutics was founded by experts in DNA repair mechanisms. Extending our team’s previous fundamental ssDR studies we analyzed andgt;61,000 tumors for somatic mutations, generated isogenic mutant/wild-type cell line pairs, screened two isogenic cell line pairs with small molecule libraries, performe ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a small-molecule immunomodulator for the treatment of melanoma

    SBC: CLARADELE PHARMACEUTICALS, INCORPORATED            Topic: NCI

    SUMMARY Melanoma is the most lethal form of skin cancer with treatment costs exceeding $3 billion each year. Melanoma is successfully managed at early stages however, five-year survival rates for the advanced disease are as low as 20%. Immunotherapeutic checkpoint inhibitors (ICI) including agents that target PD1/PD-L1, have substantially improved melanoma survival rates. Unfortunately, only 35-60 ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Image-Based Quantification and Analysis of Longitudinal Lung Nodule Deformations

    SBC: KITWARE INC            Topic: NIBIB

    DESCRIPTION (provided by applicant): Image-based evaluation of pathologies over time is complicated by variability in image acquisition and patient positioning, deformations due to respiratory and cardiac motion, and the clinical standard in radiology of comparing unaligned images. This application proposes a computational method for longitudinal image analysis that captures, illustrates and quant ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. A cloud-based digital health navigation program for colorectal cancer screening

    SBC: DIGITAL HEALTH NAVIGATION SOLUTIONS, INC.            Topic: 102

    Over 30% of age-eligible Americans fail to receive recommended screening for colorectal cancer (CRC), the second leading cause of cancer death in the United States. Multilevel barriers explain why so many Americans fail to receive routine CRC screening. Patients report a lack of knowledge about the need for screening or their screening options, and many view screening as messy, uncomfortable, or e ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer

    SBC: MIRIMUS INC            Topic: NCI

    Abstract Colorectal cancer (CRC) is the third most diagnosed cancer in the USA and accounts for more than 600,000 deaths annually worldwide, primarily due to relapse with highly aggressive, chemo-resistant disease characterized by poorly differentiated cancer cells with stem cell-like properties. A common signature of these chemo-resistant tumors is dysregulation of Notch receptor signaling, as we ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Examination of a novel potential therapy for autonomic dysreflexia

    SBC: Dignify Therapeutics LLC            Topic: NINDS

    PROJECT SUMMARY/ABSTRACT Autonomic dysreflexia (AD) is a potentially life-threatening hypertensive crisis that predominantly affects individuals with a spinal cord injury (SCI) above T6. AD can be triggered idiopathically or by distention or manipulation of pelvic visceral organs, especially the bladder and bowel, which can occur with catheterization and fecal evacuation procedures that are necess ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government